Autoimmune Hemolytic Anemia Treatment Market
According to Intent Market Research, the Autoimmune Hemolytic Anemia Treatment Market is expected to grow from USD 0.7 billion in 2023 at a CAGR of 5.9% to touch USD 1.0 billion by 2030. The Autoimmune Hemolytic Anemia Treatment Market is dominated by key players such as Pfizer Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Sanofi S.A., Novartis AG, AstraZeneca plc, Amgen Inc., Eli Lilly and Company, Johnson & Johnson Services, Inc., Biogen Inc., Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc., Merck & Co., Inc., CSL Behring, BioMarin Pharmaceutical Inc.